Back to top

cancer: Archive

Kinjel Shah

Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025

J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.

AZNNegative Net Change NVSPositive Net Change JNJPositive Net Change PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change ALLOPositive Net Change

Urmimala Biswas

TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?

GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.

AZNNegative Net Change GHNegative Net Change TEMNegative Net Change

Ekta Bagri

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

BMYNegative Net Change PFENegative Net Change

Sundeep Ganoria

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.

VRTXNegative Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Kinjel Shah

Top Cancer Stocks to Supercharge Your 2025 Portfolio

Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.

AZNNegative Net Change NVSPositive Net Change BMYNegative Net Change PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change FATEPositive Net Change

Ekta Bagri

Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

BMYNegative Net Change AMGNPositive Net Change

Sundeep Ganoria

Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings

Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.

JAZZNegative Net Change AMRXNegative Net Change

Ekta Bagri

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.

BMYNegative Net Change MRKNegative Net Change GILDPositive Net Change

Kinjel Shah

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.

AZNNegative Net Change NVSPositive Net Change PFENegative Net Change ABBVNegative Net Change VSTMNegative Net Change RLAYPositive Net Change PYXSPositive Net Change

Urmimala Biswas

Tap Into the Silver Economy Boom With These Aging Demographics Stocks

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

ABTPositive Net Change NVOPositive Net Change RMDPositive Net Change DXCMNegative Net Change EXASNegative Net Change TNDMNegative Net Change

Ahan Chakraborty

Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?

Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.

RHHBYNegative Net Change MRKNegative Net Change BAYRYPositive Net Change RXRXPositive Net Change

Bryan Hayes

Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025

Despite a correction to begin the year, there are a few pockets of the market that are working.

GILDPositive Net Change JAZZNegative Net Change

Bryan Hayes

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

During this time of heightened market volatility, it pays to be invested in the right places.

GILDPositive Net Change

Moumi Mondal

Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?

Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.

HOLXPositive Net Change MASIPositive Net Change GMEDNegative Net Change

Moumi Mondal

Should You Bet on HOLX Stock This Breast Cancer Awareness Month?

Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?

ABTPositive Net Change HOLXPositive Net Change QGENNegative Net Change

Neena Mishra

Why Biotech ETFs Are Beating the Market

: Biotech stocks are poised to benefit from lower rates

REGNPositive Net Change GILDPositive Net Change IBBNegative Net Change XBINegative Net Change SBIOPositive Net Change

Debanjana Dey

Zacks Initiates Coverage of Precipio With Outperform Recommendation

Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.

PRPONegative Net Change

Kevin Cook

Bull of the Day: NVIDIA (NVDA)

After Computex, I raised my price target to $200 because Wall Street still has no idea what's coming

NVDANegative Net Change

Sundeep Ganoria

Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.

GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNAPositive Net Change

Shaun Pruitt

Top Medical Stocks to Buy for Growth & Performance

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

HAEPositive Net Change HALONegative Net Change NBIXNo Net Change

Kinjel Shah

Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

BMYNegative Net Change PFENegative Net Change BNTXNegative Net Change

Kinjel Shah

Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

JNJPositive Net Change PFENegative Net Change NVOPositive Net Change LLYNegative Net Change

Shaun Pruitt

3 Attractive Medical Stocks to Buy After Earnings

Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.

MCKPositive Net Change EXELNegative Net Change EHCNegative Net Change

Kevin Cook

Bull of the Day: NeoGenomics (NEO)

Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite

NEOPositive Net Change NTRAPositive Net Change GHNegative Net Change